Connection

CRISTIAN COARFA to Protein Kinase Inhibitors

This is a "connection" page, showing publications CRISTIAN COARFA has written about Protein Kinase Inhibitors.
Connection Strength

0.472
  1. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019 01 15; 9(2):4.
    View in: PubMed
    Score: 0.119
  2. Targeting nuclear ?-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. 2019 06; 33(6):1373-1386.
    View in: PubMed
    Score: 0.118
  3. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia. 2017 03; 31(3):678-687.
    View in: PubMed
    Score: 0.102
  4. MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma. J Invest Dermatol. 2016 09; 136(9):1920-1924.
    View in: PubMed
    Score: 0.099
  5. RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. Br J Cancer. 2021 01; 124(1):191-206.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.